Ferulic acid lipid nano capsules versus its native form in alleviating diabetic nephropathy induced in rats through TGF-β1/Hippo pathway crosstalk modulation.

Diabetic nephropathy is one of the most common leading causes of end-stage renal disease with multifactorial pathophysiological mechanisms. TGF-β1 and Hippo pathway have been reported to have significant role in different kidney diseases. In addition, ferulic acid (FA) has been proposed to have pharmacological actions in different disorders such as Alzheimer, diabetes mellitus, kidney, and cardiovascular diseases but with limited oral use due to poor absorbance and bioavailability. So, recent trends aim to include FA in nano-formulations to improve its absorbance and bioavailability and to make best use of its pharmacological actions when administered orally. Thirty Sprague Dawley male rats were divided into five groups (n = 6). After 28 days, rats were sacrificed, serum and kidney tissue were isolated, histopathological examination, serum creatinine level and oxidative status biomarkers in kidney tissue were estimated, besides ELISA measurements of TGF-β1, PTEN, COX2, and GLUT3 and the relative gene expressions of MST1 and TEAD4 by qRT-PCR. Treated groups show improvement of the investigated parameters in variable degrees. Noteworthy, FA nano-formulation shows superior action over double of the native form.